EGFR and neoplasm: Oncogenic signaling activated in a persistent tumor is inevitably affected by the tumor microenvironment [10]; crosstalk between a persistent tumor and the tumor microenvironment, which may involve tumor-associated macrophages and cancer-associated fibroblasts, can contribute to EGFR-TKI resistance [11,12].